Abstract 2579
Background
NSR-SCC is a rare subset of bladder tumors distinct from urothelial carcinoma (UC). Most studies that have assessed molecular biomarkers in bladder cancer have been limited to UC. We aim to characterize the genomic profile of NSR-SCC and to correlate genomic alterations with survival outcomes.
Methods
This was a retrospective study of NSR-SCC patients (pts) at Princess Margaret Cancer Centre. Patient demographics, risk factors, disease characteristics, treatment modalities, and survival outcomes were collected for eligible pts. Genomic DNA and complementary DNA were analyzed using Oncomine® V3 assay, a targeted NGS platform. Overall survival (OS) was estimated by Kaplan-Meier (log-rank). Uni- (UVA) and multi-variate (MVA) analysis (Cox-regression) was used to evaluate the impact of patient and genomic characteristics on OS.
Results
We identified 11 pts with NSR-SCC from 2002-2017, with median age 71 years (range 46-86) and 7 were male. Nine pts had muscle invasive, 1 superficial stage and 1 distant metastasis. Nine pts had radical cystectomy and LN dissection. Eight pts had pT3 or pT4 with N0 and 6 were grade 2. Median OS was 12.5 months (95 % CI 7.7- 17.2 months). Common point mutations were identified in TERT (73%), TP53 (73%), PIK3CA (27%), CREBBP (18%), FBXW7 (18%), and PTEN (18%). Amplifications were identified in EGFR (18%), FGF3 (18%), CCND1 (18%), and FGF19 (18%). Additional mutations were detected at a frequency <10%. On UVA, only bladder irritants (e.g. prior radiation, urinary catheter, infection) were associated with improved OS (HR = 0.091; p = 0.031). A limited MVA didn’t identify any significant prognostic genomic abnormalities: TP53 (HR = 2.2; 95%CI: 0.3-17; p = 0.425), TERT (HR = 1.45; 95%CI: 0.2-10.2; p = 0.70) and PIK3CA (HR = 0.46; 95%CI: 0.1- 2.0; p = 0.31).
Conclusions
In this NSR-SCC series, we identified a number of actionable genomic alterations that may be targeted with drugs. No mutation was able to define different prognostic groups. Many of these aberrations were seen in UC. Biomarker driven studies in UC should consider enrollment of NSR-SCC pts who harbor these putative mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aaron Hansen.
Funding
Astellas.
Disclosure
A.G. Sacher: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self): Merck; Honoraria (self): Genentech-Roche. G. Kulkarni: Advisory / Consultancy: Janssen; Advisory / Consultancy: Astellas; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Ferring; Advisory / Consultancy: Sanofi. A. Zlotta: Advisory / Consultancy: Sanofi; Advisory / Consultancy: Ferring; Advisory / Consultancy: Janssen. A.R. Hansen: Advisory / Consultancy, Research grant / Funding (self): Genentech; Advisory / Consultancy, Research grant / Funding (self): Roche; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): GSK; Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers; Advisory / Consultancy, Research grant / Funding (self): Squibb; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract